



Complete Summary

TITLE

Venous thromboembolism (VTE): percentage of adult patients who have a high clinical pretest probability for pulmonary embolism (PE) who received low molecular weight heparin (LMWH) during evaluation.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Venous thromboembolism. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Feb. 91 p. [202 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of adult patients who have a high clinical pretest probability for pulmonary embolism (PE) who received low molecular weight heparin (LMWH) during evaluation.

RATIONALE

The priority aim addressed by this measure is to prevent progression or recurrence of thromboembolic disease.

PRIMARY CLINICAL COMPONENT

Venous thromboembolism (VTE); pulmonary embolism (PE); high clinical pretest probability; low molecular weight heparin (LMWH)

DENOMINATOR DESCRIPTION

Total number of adult patients with a documented high clinical pretest probability of pulmonary embolism (PE) (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

NUMERATOR DESCRIPTION

Total number of adult patients with a documented high clinical pretest probability of pulmonary embolism (PE) receiving low molecular weight heparin (LMWH) during the evaluation for PE

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Venous thromboembolism.](#)

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

TARGET POPULATION AGE

Age greater than or equal to 18 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

Adults 18 years and older suspected of having a pulmonary embolism (PE)

A list of all adult patients with a documented high clinical pretest probability of PE during the previous target period. The medical records can be reviewed to determine if low molecular weight heparin (LMWH) was used during evaluation.

Data may be collected semiannually.

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

Total number of adult patients with a documented high clinical pretest probability of pulmonary embolism (PE)*

*Model for Predicting Clinical Pretest Probability for PE:

- Clinical signs and symptoms of deep vein thrombosis (DVT) (minimum of leg swelling and pain with palpation of the deep veins) -- 3 points
- Alternative diagnosis is less likely -- 3 points
- Heart rate greater than 100 -- 1.5 points
- Immobilization or surgery in previous 4 weeks -- 1.5 points
- Previous DVT/PE -- 1.5 points
- Hemoptysis -- 1 point
- Malignancy (active or treated in the last 6 months or palliative) -- 1 point

Score less than 2 = low clinical pretest probability

Score 2-6 = moderate clinical pretest probability

Score more than 6 = high clinical pretest probability

Exclusions

Unspecified

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Clinical Condition

DENOMINATOR TIME WINDOW

Time window precedes index event

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Total number of adult patients with a documented high clinical pretest probability of pulmonary embolism (PE) receiving low molecular weight heparin (LMWH) during the evaluation for PE

Exclusions

Unspecified

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Episode of care

DATA SOURCE

Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Percentage of adult patients who have a high clinical pretest probability for PE who received low molecular weight heparin (LMWH) during evaluation.

MEASURE COLLECTION

[Venous Thromboembolism Measures](#)

DEVELOPER

Institute for Clinical Systems Improvement

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2006 Feb

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Venous thromboembolism. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Feb. 91 p. [202 references]

MEASURE AVAILABILITY

The individual measure, "Percentage of adult patients who have a high clinical pretest probability for PE who received low molecular weight heparin (LMWH) during evaluation," is published in "Health Care Guideline: Venous Thromboembolism." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

NQMC STATUS

This NQMC summary was completed by ECRI on May 1, 2006.

COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2006 National Quality Measures Clearinghouse

Date Modified: 9/25/2006



